Population Pharmacokinetics of Mirvetuximab Soravtansine in Patients with Folate Receptor-α Positive Ovarian Cancer: the Antibody-Drug Conjugate, Payload and Metabolite.

There is no need for dose adjustment due to covariate effects for mirvetuximab soravtansine administered at the recommended dose of 6 mg/kg based on adjusted ideal body weight. Dose adjustment is not required for patients with mild or moderate renal impairment, mild hepatic impairment, or when concomitant weak and moderate CYP3A4 inhibitors are used.